NASDAQ:KYMR | Free Cash Flow | Kymera Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$88.84M$434,000.00-$89.27M
2025-12-31-$66.75M$106,000.00-$66.85M
2025-03-31-$79.15M$467,000.00-$79.62M
2024-12-31-$61.78M$936,000.00-$62.72M
2024-03-31-$39.59M$7.4M-$46.99M
2023-12-31$8.05M$11.63M-$3.58M
2023-03-31-$43.97M$4.01M-$47.98M
2022-12-31-$39.54M$373,000.00-$39.91M
2022-03-31-$40.3M$482,000.00-$40.78M
2021-12-31-$38.35M$501,000.00-$38.85M
2021-03-31-$22.82M$164,000.00-$22.99M
2020-12-31-$20.07M$1.44M-$21.51M
2020-03-31-$12.06M$1.4M-$13.45M
2019-12-31-$10.8M$199,000.00-$11M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$232.89M$1.45M-$234.34M
2024-12-31-$194.5M$12.84M-$207.34M
2023-12-31-$102.83M$34.48M-$137.31M
2022-12-31-$153.09M$2.84M-$155.92M
2021-12-31-$128.95M$1.6M-$130.54M
2020-12-31$88.13M$9.1M$79.03M
2019-12-31$17.91M$532,000.00$17.37M